Influenza News and Research

Latest Influenza News and Research

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Dr Glynis Neagle, Synexus' Chief Medical Officer will be discussing the challenges facing global vaccine trials at the World Vaccine Congress in Washington this week.

From AES - Accelerated Enrollment Solutions 11 Apr 2011

Viral infection likely to encourage pneumonia spread

Bacteria that cause pneumonia and meningitis are only able to spread when individuals are infected with flu, says a scientist reporting at the Society for General Microbiology's Spring Conference in Harrogate. The work could have implications for the management of influenza pandemics and could help reduce incidence of pneumococcal infections in very young children, who are more susceptible to disease.

11 Apr 2011

Immunization does not increase emergency room visit in children with inherited disorders

Children with inborn errors of metabolism received vaccines on the same immunization schedule as did healthy infants, according to Kaiser Permanente Vaccine Study Center scientists who examined the Kaiser Permanente Northern California population. In addition, immunization was not associated with significant increases in emergency room visits or hospitalizations during the month following vaccination, according to Nicola Klein, MD, PhD, lead author of the study and co-director of the Kaiser Permanente Vaccine Study Center.

11 Apr 2011

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee recommended suspension of enrollment.

11 Apr 2011

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates resulted in significant reduction in lung tissue presence of leukocytes, and in particular, that of eosinophils in a lethal influenza infection animal model.

8 Apr 2011

Top 10 global pharmaceutical company, Medicago sign deal to develop non-influenza vaccine

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.

7 Apr 2011

Quest Diagnostics Simplexa molecular test receives bronze award for best new product

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa™ molecular test on the 3M™ Integrated Cycler was honored with a bronze award for best new science and medical diagnostic product during the 2011 Edison Awards gala ceremony last night in New York City.

From Quest Diagnostics 7 Apr 2011

Study: Migratory birds play a key role in avian influenza transmission

The persistence and recurrence of H5N1 avian influenza in endemic regions can largely be blamed on movement and infection by migratory birds. Trade in poultry, poultry products and caged birds, and movement of wild birds also account for H5N1 prevalence in these areas.

6 Apr 2011

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

Aragen Bioscience, Inc., today announced it is a subcontractor on a National Institute of Allergy and Infectious Diseases contract for the preclinical development of monoclonal antibodies for the prevention and treatment of infectious diseases.

6 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

Novavax, Inc. announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today. In its tenth annual list of promising clinical compounds, R&D Directions cited Novavax's virus-like-particle technology as a promising new approach to producing vaccines to prevent seasonal, H1N1 and avian influenza. The list reflects the current interests of industry observers and analysts and is described in the magazine's March 2011 issue.

5 Apr 2011

OncoSec acquires certain assets of Inovio

OncoSec Medical Incorporated, a developer of innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today that on March 24, 2011 it completed its acquisition of certain assets of Inovio Pharmaceuticals, Inc. and entered into a license agreement with Inovio, pursuant to the terms of an asset purchase agreement with Inovio entered into on March 14, 2011.

4 Apr 2011

Research roundup: Patient's income and electronic health records; high deductible plans; raising Medicare age

Healthcare Spending And Preventive Care In High-Deductible And Consumer-Directed Health Plans - Authors analyzed data from more than 800,000 families insured during 2004 and 2005 through one of 53 large employers in U.S., about half offering the high-deductible or consumer-directed plans.

1 Apr 2011

Biota receives US$231 million BARDA contract to advance laninamivir development

Biota Holdings Limited advises that the Office of Biomedical Advanced Research and Development Authority within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services has awarded up to an estimated US$231 million contract to its wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of laninamivir.

1 Apr 2011

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

A contract has been awarded to develop a long-acting single-dose antiviral drug for use in the United States, the U.S. Biomedical Advanced Research and Development Authority announced today.

1 Apr 2011

Biota wins U.S. drug development contract for Laninamivir

Australian biotechnology company Biota Holdings revealed its US subsidiary has won a five year $US231 million ($A224.36 million) contract from the US government to develop a long-acting, single-dose flu drug for sale in the US. Shares in the Melbourne-based drug development company jumped 60 cents, or 57%, to $1.60 at the market open today falling back to $1.43, 1pm (AEST).

31 Mar 2011

Sinovac reports fourth quarter net sales of $9.1 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended December 31, 2010.

31 Mar 2011

International experts meet to focus on impact of vaccines on global health at a time of public scepticism and complacency

International experts gather in Prague today for a three day meeting focused on the impact of vaccines on public health, at a time of increasing concern that public scepticism and complacency could undermine the positive impact of current and future vaccine campaigns.

31 Mar 2011

WHO Director-General responds to draft report on agency's handling of H1N1 pandemic

WHO Director-General Margaret Chan on Monday responded to the first results of a probe into the agency's response to the H1N1 pandemic, Agence France-Presse reports.

30 Mar 2011

Scientist develops new model to understand peoples' behaviors during flu outbreaks

When influenza pandemics arrive, the specter of disease spread through person-to-person contact can mean that schools close, hand sanitizer sales rise, and travellers stay home. But is severing social and business interactions with our neighbors really better than taking a chance on getting sick?

29 Mar 2011

Influenza News and Research

Latest Influenza News and Research

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Viral infection likely to encourage pneumonia spread

Immunization does not increase emergency room visit in children with inherited disorders

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

Top 10 global pharmaceutical company, Medicago sign deal to develop non-influenza vaccine

Quest Diagnostics Simplexa molecular test receives bronze award for best new product

Study: Migratory birds play a key role in avian influenza transmission

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

OncoSec acquires certain assets of Inovio

Research roundup: Patient's income and electronic health records; high deductible plans; raising Medicare age

Biota receives US$231 million BARDA contract to advance laninamivir development

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

Biota wins U.S. drug development contract for Laninamivir

Sinovac reports fourth quarter net sales of $9.1 million

International experts meet to focus on impact of vaccines on global health at a time of public scepticism and complacency

WHO Director-General responds to draft report on agency's handling of H1N1 pandemic

Scientist develops new model to understand peoples' behaviors during flu outbreaks

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Influenza News and Research

Latest Influenza News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in